All Stories

  1. Fractional flow reserve (FFR) as a guide to treat coronary artery disease
  2. Fractional flow reserve to guide and to assess coronary artery bypass grafting
  3. Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome
  4. Acute coronary syndromes in patients with multivessel disease
  5. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial
  6. Impact of Chronic Kidney Disease on Platelet Reactivity and Outcomes of Patients Receiving Clopidogrel and Undergoing Percutaneous Coronary Intervention
  7. Advances in Induced Pluripotent Stem Cells, Genomics, Biomarkers, and Antiplatelet Therapy Highlights of the Year in JCTR 2013
  8. Percutaneous revascularization strategies in small-vessel disease
  9. ACEF and clinical SYNTAX score in the risk stratification of patients with heavily calcified coronary stenosis undergoing rotational atherectomy with stent implantation
  10. Monocyte–Platelets Aggregates as Cellular Biomarker of Endothelium-Dependent Coronary Vasomotor Dysfunction in Patients with Coronary Artery Disease
  11. Quantitative angiography and optical coherence tomography for the functional assessment of nonobstructive coronary stenoses: Comparison with fractional flow reserve
  12. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease
  13. Double-Blind Parallel Placebo-Controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients with Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention: the MEDCOR Trial
  14. TCT-656 Beneficial Effects Of Manual- Versus Pump Contrast Injection On Image Quality And ContRast Demand During Optical Coherence Tomography: The BIRD Study
  15. TCT-297 A new prognostic risk score including platelet reactivity for bleeding after percutaneous coronary intervention via the femoral approach
  16. Letter by Mangiacapra and Barbato Regarding Article, “Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease”
  17. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus
  18. Long-term clinical outcome after fractional flow reserve– versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts
  19. Optimization of Tryton Dedicated Coronary Bifurcation System With Coregistration of Optical Coherence Tomography and Fractional Flow Reserve
  20. Efficacy of Clopidogrel Reloading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention During Chronic Clopidogrel Therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 R...
  21. Quantitative Assessment of the Coronary Microvasculature
  22. Retrospective multicenter observational study of the interventional management of coronary disease in the very elderly: The NINETY
  23. Association of Biomarkers of Lipid Modification with Functional and Morphological Indices of Coronary Stenosis Severity in Stable Coronary Artery Disease
  24. VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis Severity in EverydaY Practice)
  25. St. John’s Wort in Patients Non-responders to Clopidogrel Undergoing Percutaneous Coronary Intervention: a Single-Center Randomized Open-Label Trial (St. John’s Trial)
  26. Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention
  27. Influence of transradial versus transfemoral diagnostic heart catheterisation on peripheral vascular endothelial function
  28. Contrast-Induced Nephropathy in Patients Undergoing Primary Percutaneous Coronary Intervention Without Acute Left Ventricular Ejection Fraction Impairment
  29. CLOPIDOGREL RELOADING IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PCI ON CHRONIC CLOPIDOGREL THERAPY: RESULTS OF THE ARMYDA-8 RELOAD-ACS (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED TRIAL
  30. Intracoronary Enalaprilat to Reduce Microvascular Damage During Percutaneous Coronary Intervention (ProMicro) Study
  31. CRT-65 Multi Center, Prospective, Randomized, Single Blind, Consecutive Enrollment Evaluation Of The Elixir DESyne Tm Novolimus-eluting Coronary Stent System With Durable Polymer Compared To The Endeavor Zotarolimus-eluting Coronary Stent System: 3-yea...
  32. Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor
  33. Chronic total occlusions for intermediate volume operators: An antegrade step-up algorithm allows high success in easy and intermediate difficult CTO lesions
  34. Clinical Implications of Platelet—Vessel Interaction
  35. von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina
  36. TCT-144 Impact of chronic kidney disease on platelet reactivity and clinical outcomes of patients undergoing percutaneous coronary intervention
  37. TCT-56 Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding events after percutaneous coronary intervention
  38. TCT-282 The REMEDEE OCT study: A prospective randomized study of the early vascular healing of a novel Dual Therapy Stent in comparison with an everolimus eluting stent
  39. Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of ...
  40. TCT-657 Multi Center, Prospective, Randomized, Single Blind, Consecutive Enrollment Evaluation Of Elixir DESyneTM Novolimus-Eluting Coronary Stent System With Durable Polymer To Endeavor Zotarolimus-Eluting Coronary Stent System: 3-Year Clinical and 9-...
  41. Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease
  42. High cholesterol levels are associated with coronary microvascular dysfunction
  43. Influence of rs5065 Atrial Natriuretic Peptide Gene Variant on Coronary Artery Disease
  44. NT-proANP circulating level is a prognostic marker in stable ischemic heart disease
  45. A Therapeutic Window for Platelet Reactivity for Patients Undergoing Elective Percutaneous Coronary Intervention
  46. Comparison of drug-eluting versus bare-metal stents after rotational atherectomy for the treatment of calcified coronary lesions
  47. 283 Clinical impact of fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with small coronary vessel lesions
  48. 014 Five-year clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting
  49. 012 Five-year clinical outcome in elderly population with small vessel disease treated with drug-eluting versus bare-metal stenting
  50. Reperfusion strategies for acute coronary syndrome
  51. Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting
  52. Long-Term Follow-Up After Fractional Flow Reserve–Guided Treatment Strategy in Patients With an Isolated Proximal Left Anterior Descending Coronary Artery Stenosis
  53. Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
  54. From SYNTAX to FAME, a paradigm shift in revascularization strategies
  55. The reconciliation of pressure and light
  56. Transcriptional fingerprint of human whole blood at the site of coronary occlusion in acute myocardial infarction
  57. Treatment of diabetic patients with non-ST-elevation myocardial infarction
  58. Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel
  59. Autologous cell therapy for enhanced endovascular repair after coronary stent implantation
  60. Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel
  61. Fractional Flow Reserve for the Assessment of Nonculprit Coronary Artery Stenoses in Patients With Acute Myocardial Infarction
  62. Comparison of 600 Versus 300-mg Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Angioplasty
  63. Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST...
  64. Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome
  65. Comparison of Platelet Reactivity and Periprocedural Outcomes in Patients With Versus Without Diabetes Mellitus and Treated With Clopidogrel and Percutaneous Coronary Intervention
  66. Effective Radiation Dose, Time, and Contrast Medium to Measure Fractional Flow Reserve
  67. Thrombus aspiration in primary percutaneous coronary intervention in high‐risk patients with ST‐elevation myocardial infarction: A real‐world registry
  68. Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization
  69. Biomarkers of vulnerable plaque: the missing link with ischemia
  70. A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study
  71. Point-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention
  72. Relation of Endothelial Function to Residual Platelet Reactivity After Clopidogrel in Patients With Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention
  73. High Residual Platelet Reactivity After Clopidogrel
  74. Human coronary atherosclerosis modulates cardiac natriuretic peptide release
  75. Diastolic function and BNP changes during exercise predict oxygen consumption in chronic heart failure patients
  76. Role of adrenergic receptors in human coronary vasomotion
  77. In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction
  78. Relation of Low Response to Clopidogrel Assessed With Point-of-Care Assay to Periprocedural Myonecrosis in Patients Undergoing Elective Coronary Stenting for Stable Angina Pectoris
  79. Direct Stenting for Stable Angina Pectoris Is Associated With Reduced Periprocedural Microcirculatory Injury Compared With Stenting After Pre-Dilation
  80. Drug-Eluting Stent Implantation
  81. GLU-27 variant of β2-adrenergic receptor polymorphisms is an independent risk factor for coronary atherosclerotic disease
  82. Assessment of Renal Flow and Flow Reserve in Humans
  83. Effect of Phentolamine on the Hyperemic Response to Adenosine in Patients With Microvascular Disease
  84. Role of β 2 Adrenergic Receptors in Human Atherosclerotic Coronary Arteries
  85. Tissue doppler imaging predicts recovery of left ventricular function after recanalization of an occluded coronary artery
  86. Effects of intravenous dobutamineon coronary vasomotion in humans
  87. Alpha-blockade in patients with coronary artery disease: Implications for fractional flow reserve measurements
  88. Myocardial velocity pattern during isovolumic contraction predicts recovery of contractile function after revascularization in patients with segmental dysfunction
  89. Direct stenting
  90. Intracoronary Ultrasound Imaging: Universal Praise, Qualified Adoption
  91. ROLE OF THE SYMPATHETIC NERVOUS SYSTEM IN CARDIAC REMODELING IN HYPERTENSION
  92. Systemic hypertension and coronary artery disease: the link